Gainers

• Serina Therapeutics (AMEX:SER) shares moved upwards by 36.7% to $1.75 during Thursday's pre-market session. The company's market cap stands at $13.8 million.
• Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 29.49% to $7.64. The company's market cap stands at $7.2 million.
• Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares increased by 16.54% to $0.4. The company's market cap stands at $2.5 million.
• Spectral AI (NASDAQ:MDAI) stock moved upwards by 13.31% to $1.36. The company's market cap stands at $36.8 million.
• Passage Bio (NASDAQ:PASG) shares rose 12.26% to $7.89. The company's market cap stands at $22.3 million.
• AlphaTON Capital (NASDAQ:ATON) stock moved upwards by 11.51% to $0.39. The market value of their outstanding shares is at $8.2 million.

Losers

• Reviva Pharmaceuticals (NASDAQ:RVPH) stock fell 47.6% to $0.98 during Thursday's pre-market session. The market value of their outstanding shares is at $10.9 million.
• Quince Therapeutics (NASDAQ:QNCX) stock decreased by 17.94% to $0.08. The market value of their outstanding shares is at $5.4 million.
• Agilon Health (NYSE:AGL) stock decreased by 15.27% to $0.5. The market value of their outstanding shares is at $244.8 million.
• AIM ImmunoTech (AMEX:AIM) shares declined by 11.28% to $0.91. The company's market cap stands at $4.0 million.
• Lunai Bioworks (NASDAQ:LNAI) shares fell 10.41% to $0.36. The market value of their outstanding shares is at $9.7 million.
• Nasus Pharma (AMEX:NSRX) shares fell 9.93% to $2.36. The market value of their outstanding shares is at $30.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.